SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurobiological Tech (NTII)
NTII 0.00010000.0%Dec 26 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dr. John M. de Castro who wrote (567)5/23/1999 7:47:00 PM
From: NeuroInvestment  Read Replies (2) of 1494
 
Before getting too excited about the Swedish study results, two things must be kept in mind;
1) It relied upon 'soft' behavioral measures, and the FDA does not like this kind of data. They prefer mortality (easy to measure, good interrater reliability) but in this instance, will insist upon standard cognitive measures which are more 'objective.' One can make a solid case for why behavioral measures are more meaningful, but....the ongoing studies do include such cognitive instruments.
2) The Alzheimer's target is not that important to NTI. Merz gets to keep 92% of the royalties paid by a marketing partner for AD...the neuropathic pain and AIDS-dementia targets are smaller in terms of market size, but NTI gets 75% of the royalties on net sales, paying 12% of that to Children's. To me, it is the lack of side effects that is most impressive, especially in an elderly population. That raises optimism regarding the safety profile in NP and AIDS-D--and as Dr. de Castro has noted, memantine comes from a class of drugs that has been plagued by adverse side effects (vacuolization, psychotomimetic effects, catatonia) to the point of being 'blackballed' by many Big Pharmas. To provide neuroprotective and analgesic effects without such side effects is crucial--and thus far the safety profile looks good.
NeuroInvestment (www.neuroinvestment.com)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News